The Role of Norepinephrine in the Treatment of Depression
J Clin Psychiatry 1999;60(9):623-631
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Despite recent strides in treatment, depression remains a common, costly, and often deadly disease, Dr. Charles B. Nemeroff stated. More than 1.2 million persons are diagnosed with an affective disorder in the United States each year, an incidence of approximately 5% to 10%, and depression is more prevalent than arthritis, diabetes, or heart disease. Depression is also a costly disease: in 1990 it was estimated that in the United States alone the cost of depression approached $44 billion, including direct costs for medication, physician services, etc., as well as indirect costs such as increased morbidity, excessive absenteeism, and reduced productivity. Depression also has a high mortality: up to 15% of severely depressed patients will ultimately commit suicide.